Jul 12, 2021 Nephros has entered into an agreement to acquire GenArraytion (pressrelease).

“The strategic acquisition of GenArraytion further cements our position in the emerging PCR testing market for waterborne pathogens, expanding our abilities to detect and mitigate the spread of infectious disease in premise plumbing,” said Andy Astor, Chief Executive Officer of Nephros.

Nephros (NASDAQ: NEPH) is based in South Orange, New Jersey, United States. a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. The company operates through three segments: Water Filtration, Pathogen Detection, and Renal Products. Its ultrafilters are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company develops and sells water testing systems to provide actionable data on waterborne pathogens; and medical device products for patients with renal disease, including a 2nd generation hemodiafiltration system for the treatment of patients with end stage renal disease. 

Acquirer’s Website: nephros.com

GenArraytion is based in Rockville, Maryland, United States. “GenArraytion is a veteran-owned small business offering products and services for medical diagnostics, including tick- and mosquito-borne disease and surveillance, epidemiology and source tracking, food and water testing, biodefense and environmental monitoring.”

Acquirer’s Website: www.genarraytion.com/